Literature DB >> 9431939

Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method.

S G Revankar1, W R Kirkpatrick, R K McAtee, A W Fothergill, S W Redding, M G Rinaldi, T F Patterson.   

Abstract

Trailing endpoints remain a problem in antifungal susceptibility testing using the National Committee for Clinical Laboratory Standards (NCCLS) method. For isolates for which trailing endpoints are found, MICs of < or = 1 microg/ml at 24 h and of > 64 microg/ml at 48 h are usually observed. In a study of human immunodeficiency virus (HIV)-infected patients with oropharyngeal candidiasis, we identified three patients with multiple serial isolates for which trailing endpoints were observed with fluconazole. At 24 h, MICs were generally < or = 1 microg/ml by both broth macro- and microdilution methods. However, at 48 h, MICs were > 64 microg/ml, while the organism remained susceptible by agar dilution testing with fluconazole. Most episodes of oropharyngeal candidiasis with trailing-endpoint isolates responded to doses of fluconazole as low as 100 mg/day. Two patients had both susceptible and trailing-endpoint isolates by NCCLS broth macro- and microdilution testing; these isolates were found to be the same strain by pulsed-field gel electrophoresis using restriction fragment length polymorphisms. Another patient had two different strains, one for which trailing endpoints were observed and one which was susceptible at 48 h. Trailing endpoints may be seen with selected isolates of a strain or may be a characteristic finding for most or all isolates of a strain. In addition, with isolates for which trailing endpoints are observed, reading the endpoint for the NCCLS method at 24 h may be more appropriate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9431939      PMCID: PMC124826     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study.

Authors:  E J Anaissie; V L Paetznick; L G Ensign; A Espinel-Ingroff; J N Galgiani; C A Hitchcock; M LaRocco; T Patterson; M A Pfaller; J H Rex; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 2.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

3.  Collaborative investigation of the accuracy and reproducibility of Sceptor Breakpoint susceptibility panels.

Authors:  G A Denys; S L Hansen; W A Pope; H Lilli; J M Hejna
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

4.  Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870.

Authors:  M A Pfaller; S A Messer; S Coffmann
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

5.  Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

Authors:  S Redding; J Smith; G Farinacci; M Rinaldi; A Fothergill; J Rhine-Chalberg; M Pfaller
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

6.  Simple method for detecting fluconazole-resistant yeasts with chromogenic agar.

Authors:  T F Patterson; S G Revankar; W R Kirkpatrick; O Dib; A W Fothergill; S W Redding; D A Sutton; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

7.  Comparative evaluation of macrodilution and chromogenic agar screening for determining fluconazole susceptibility of Candida albicans.

Authors:  T F Patterson; W R Kirkpatrick; S G Revankar; R K McAtee; A W Fothergill; D I McCarthy; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

8.  Minimum bactericidal concentration of sulfamethoxazole-trimethoprim for Haemophilus influenzae: correlation with prophylaxis.

Authors:  L A Kirven; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

9.  Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.

Authors:  M L Cameron; W A Schell; S Bruch; J A Bartlett; H A Waskin; J R Perfect
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

10.  Quantitative antimicrobial susceptibility testing of Haemophilus influenzae and Streptococcus pneumoniae by using the E-test.

Authors:  J H Jorgensen; A W Howell; L A Maher
Journal:  J Clin Microbiol       Date:  1991-01       Impact factor: 5.948

View more
  44 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species.

Authors:  Manuel Cuenca-Estrella; Wendy Lee-Yang; Meral A Ciblak; Beth A Arthington-Skaggs; Emilia Mellado; David W Warnock; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 3.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

4.  Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.

Authors:  M A Pfaller; L B Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

5.  Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp.

Authors:  M Cuenca-Estrella; T M Díaz-Guerra; E Mellado; J L Rodríguez-Tudela
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

6.  Comparative evaluation of a new fluorescent carboxyfluorescein diacetate-modified microdilution method for antifungal susceptibility testing of Candida albicans isolates.

Authors:  Robert S Liao; Robert P Rennie; James A Talbot
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

7.  Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates.

Authors:  Beth A Arthington-Skaggs; Wendy Lee-Yang; Meral A Ciblak; Joao P Frade; Mary E Brandt; Rana A Hajjeh; Lee H Harrison; Andre N Sofair; David W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.

Authors:  Hanan K Munayyer; Paul A Mann; Andrew S Chau; Taisa Yarosh-Tomaine; Jonathan R Greene; Roberta S Hare; Larry Heimark; Robert E Palermo; David Loebenberg; Paul M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Authors:  J L Lopez-Ribot; R K McAtee; L N Lee; W R Kirkpatrick; T C White; D Sanglard; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia.

Authors:  Monika Sojakova; Denisa Liptajova; Miroslav Borovsky; Julius Subik
Journal:  Mycopathologia       Date:  2004-02       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.